The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers , suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia .
Ghrelin is a hormone with multiple physiologic functions , including promotion of growth hormone release , stimulation of appetite and regulation of energy homeostasis .
Treatment with ghrelin/ghrelin-receptor agonists is a prospect i ve therapy for disease-related cachexia and malnutrition .
In vitro studies have shown high expression of ghrelin in cancer tissue , although its role including its impact in cancer risk and progression has not been established .
Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer
Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I ( IGF-I ) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 ( IGFBP-3 ) and prostate cancer risk , a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer . We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma sample s collected at baseline in a prospect i ve cohort study of 17,049 men . We used a case-cohort design , including 524 cases diagnosed during a mean of 8.7 years follow-up and a r and omly sample d subcohort of 1,826 men . The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption . The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 ( all odds ratios are between 0.82 and 1.08 ; Ptrend ≥ 0.2 ) , whereas the risk increased with baseline levels of IGFBP-3 ( Ptrend = 0.008 ) , the hazard ratio ( HR ) associated with a doubling of the concentration of IGFBP-3 being 1.70 ( 95 % confidence interval , 1.15 - 2.52 ) . The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 ( 95 % confidence interval , 1.11 - 2.00 ) . The HRs did not differ by tumor aggressiveness or age at onset ( all Ps ≥ 0.4 ) . In our study , high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer . ( Cancer Epidemiol Biomarkers Prev 2006;15(6):1137–41
The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers , suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia .
Ghrelin is a hormone with multiple physiologic functions , including promotion of growth hormone release , stimulation of appetite and regulation of energy homeostasis .
Treatment with ghrelin/ghrelin-receptor agonists is a prospect i ve therapy for disease-related cachexia and malnutrition .
In vitro studies have shown high expression of ghrelin in cancer tissue , although its role including its impact in cancer risk and progression has not been established .